IP Verse

Macrocycles As Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions Thereof, Their Use In The Treatment Of Cycstic Fibrosis, And Process For Making Them - EP3752510

The patent EP3752510 was granted to Vertex Pharmaceuticals Incorporated on Dec 7, 2022. The application was originally filed on Feb 14, 2019 under application number EP19707648A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3752510

VERTEX PHARMACEUTICALS INCORPORATED
Application Number
EP19707648A
Filing Date
Feb 14, 2019
Status
Opposition Rejected
Mar 28, 2025
Grant Date
Dec 7, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSSep 7, 2023D YOUNGADMISSIBLE

Patent Citations (21) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2004006237
DESCRIPTIONUS8865902
DESCRIPTIONWO2007134279
DESCRIPTIONWO2010019239
DESCRIPTIONWO2010037066
DESCRIPTIONWO2011019413
DESCRIPTIONWO2011119984
DESCRIPTIONWO2011127241
DESCRIPTIONWO2012027731
DESCRIPTIONWO2013112804
DESCRIPTIONWO2013130669
DESCRIPTIONWO2014015841
DESCRIPTIONWO2014071122
DESCRIPTIONWO2014078842
DESCRIPTIONWO2015160787
DESCRIPTIONWO2018227049
INTERNATIONAL-SEARCH-REPORTUS2016095858
INTERNATIONAL-SEARCH-REPORTWO2017173274
INTERNATIONAL-SEARCH-REPORTWO2018064632
INTERNATIONAL-SEARCH-REPORTWO2018107100
OPPOSITIONWO2016057572

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CUTTING, G. R. et al., Nature, (19900000), vol. 346, pages 366 - 369-
DESCRIPTION- DALEMANS et al., Nature Lond., (19910000), vol. 354, pages 526 - 528-
DESCRIPTION- DAVIES et al., New Engl. J. Med., (20180000), vol. 379, no. 17, pages 1599 - 1611-
DESCRIPTION- DAVIES et al., New Engl. J. Med., (20180000), vol. 379, no. 17, pages 1612 - 1620-
DESCRIPTION- DEAN, M. et al., Cell, (19900000), vol. 61, no. 863, page 870-
DESCRIPTION- Encyclopedia of Pharmaceutical Technology, Marcel Dekker, pages 1988 - 1999-
DESCRIPTION- J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19-
DESCRIPTION- KEREM, B-S et al., Proc. Natl. Acad. Sci. USA, (19900000), vol. 87, pages 8447 - 8451-
DESCRIPTION- KEREM, B-S. et al., Science, (19890000), vol. 245, pages 1073 - 1080-
DESCRIPTION- PASYK; FOSKETT, J. Cell. Biochem., (19950000), vol. 270, pages 12347 - 50-
DESCRIPTION- QUINTON, P. M., FASEB J., (19900000), vol. 4, pages 2709 - 2727-
DESCRIPTION- Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins-
DESCRIPTION- S. M. BERGE et al., J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19-
DESCRIPTION- VAN GOOR, F. et al., PNAS, (20090000), vol. 106, no. 44, pages 18825 - 18830-
DESCRIPTION- VAN GOOR, F. et al., PNAS, (20110000), vol. 108, no. 46, pages 18843 - 18846-
DESCRIPTION- S. L. HARBESON; R. D. TUNG, "Deuterium In Drug Discovery and Development", Ann. Rep. Med. Chem., (20110000), vol. 46, doi:doi:10.1016/B978-0-12-386009-5.00003-5, pages 403 - 417, XP055422117
DESCRIPTION- T.G. GANT, "Using deuterium in drug discovery: leaving the label in the drug", J. Med. Chem., (20140000), vol. 57, doi:doi:10.1021/jm4007998, pages 3595 - 3611, XP055139522
OPPOSITION- Anonymous, "VX-659/tezacaftor/ivacaftor for Cystic Fibrosis", (20170118), URL: https://cysticfibrosisnewstoday.com/vx-659-tezacaftor-ivacaftor-cystic-fibrosis/, XP093130419-
OPPOSITION- Armstrong Madeleine, "Galapagos goes for broke in cystic fibrosis", (20171121), URL: https://www.evaluate.com/vantage/articles/news/galapagos-goes-broke-cystic-fibrosis, XP093130423-
OPPOSITION- Armstrong Madeleine, "Vertex eyes the treble in cystic fibrosis", (20170719), URL: https://www.evaluate.com/vantage/articles/news/vertex-eyes-treble-cystic-fibrosis, XP093130424-
OPPOSITION- Jonathan Clayden, Nick Greeves, Stuart Warren, Peter Wothers, Organic Chemistry, Oxford University Press, (20010101), page 143, 144, 340, 341, XP093130416-
OPPOSITION- Ahmet Z Uluer, "Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials", THE LANCET. RESPIRATORY MEDICINE, Elsevier, Oxford, Oxford , (20230223), vol. 11, no. 6, doi:10.1016/S2213-2600(22)00504-5, ISSN 2213-2600, pages 550 - 562, XP093161417
OPPOSITION- Wang Xueqing, Liu Bo, Searle Xenia, Yeung Clinton, Bogdan Andrew, Greszler Stephen, Singh Ashvani, Fan Yihong, Swensen Andrew M, Vortherms Timothy, Balut Corina, Jia Ying, Desino Kelly, Gao Wenqing, Yong Hong, Tse Chris, Kym Philip, "Discovery of 4-[(2 R ,4 R )-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2 H -chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis", Journal of Medicinal Chemistry, American Chemical Society, US, US , (20180222), vol. 61, no. 4, doi:10.1021/acs.jmedchem.7b01339, ISSN 0022-2623, pages 1436 - 1449, XP093130421
OPPOSITION- Harbeson Scott L., Morgan Adam J., Liu Julie F., Aslanian Ara M., Nguyen Sophia, Bridson Gary W., Brummel Christopher L., Wu Lijun, Tung Roger D., Pilja Lana, Braman Virginia, Uttamsingh Vinita, "Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development", Journal of pharmacology and experimental therapeutics, American Society for Pharmacology and Experimental Therapeutics, US, US , (20170801), vol. 362, no. 2, doi:10.1124/jpet.117.241497, ISSN 0022-3565, pages 359 - 367, XP055981784

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents